

# GILEAD SCIENCES INC.

ISIN: US3755581036 WKN: 375558103 Asset Class: Stock

## Company

2021/04/22 17:02:50



Price

**66.05**

USD

Difference

-1.11% (-0.74)



## Contact Details

GILEAD SCIENCES, INC. Tel: 1-650-574-3000  
 -- Fax: 1-650-578-9264  
 333 Lakeside Drive Web: <http://www.gilead.com>  
 94404 Foster City E-mail: -

## Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Eplclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2020		2019		2018	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	15,996,000,000		30,296,000,000		35,836,000,000	
<b>Common stock capital</b>		1,000,000		1,000,000		1,000,000
<b>Fixed assets</b>	52,411,000,000		31,331,000,000		27,839,000,000	
<b>Equity capital of a company</b>		18,221,000,000		22,650,000,000		21,534,000,000
<b>Cash and cash equivalents</b>	5,997,000,000		11,631,000,000		17,940,000,000	
<b>Accrued liabilities</b>		0		0		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		11,397,000,000		9,759,000,000		10,605,000,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		38,789,000,000		29,218,000,000		31,536,000,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		9,536,000,000		6,498,000,000		6,962,000,000
<b>Total assets</b>	68,407,000,000	68,407,000,000	61,627,000,000	61,627,000,000	63,675,000,000	63,675,000,000

## Balance notes

	2020	2019	2018
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	13,600	11,800	11,000
<b>Equity ratio</b>	26.66%	36.96%	34.05%
<b>Debt-equity ratio</b>	275.04%	170.59%	193.69%

## Others

	2020	2019	2018
<b>Tax Expense Rate</b>	94.67%	-3.95%	29.99%

# GILEAD SCIENCES INC.

ISIN: US3755581036 WKN: 375558103 Asset Class: Stock

## Income statement

	2020	2019	2018
Turnover	24,642,000,000	22,322,000,000	22,214,000,000
Net income	123,000,000	5,386,000,000	5,455,000,000
EBIT	2,203,051,200	5,111,112,000	7,370,630,400
Operating income before taxes	1,669,000,000	5,160,000,000	7,799,000,000
Cash Flow	8,168,000,000	9,144,000,000	8,400,000,000
Net interest income	-984,000,000	-995,000,000	-1,077,000,000
Research and development expenses	4,857,000,000	8,306,000,000	4,198,000,000
Income taxes	1,580,000,000	-204,000,000	2,339,000,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,504,612	1,570,863	1,676,955

## Board of Directors

## Members of Management Board

Jacqueline Barton	Member of Board of Directors
Jeffrey Bluestone	Member of Board of Directors
Richard Whitley	Member of Board of Directors
Sandra Horning	Member of Board of Directors
Anthony Welters	Member of Board of Directors
Harish M. Manwani	Member of Board of Directors
Javier Rodriguez	Member of Board of Directors
Kelly Kramer	Member of Board of Directors
Kevin Lofton	Member of Board of Directors
Per Wold-Olsen	Member of Board of Directors
Daniel O'Day	Chairman of Managing Board
Linda Higgins	Member of Executive Committee
Mark Genovese	Member of Executive Committee
Merdad Parsey	Member of Executive Committee
Michael Quigley	Member of Executive Committee
Tomas Cihlar	Member of Executive Committee
William Lee	Member of Executive Committee
Andrew Dickinson	Member of Executive Committee
Brett Pletcher	Member of Executive Committee
Diane Wilfong	Member of Executive Committee